The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.
 
Merve Hasanov
No Relationships to Disclose
 
Denai R. Milton
No Relationships to Disclose
 
Serigne N. Lo
No Relationships to Disclose
 
Jeffrey E. Gershenwald
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Regeneron; Syndax
Patents, Royalties, Other Intellectual Property - mercator therpaeutics
 
Julie Simon
No Relationships to Disclose
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Innovent Biologics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Provectus; QBiotics; Regeneron
 
Richard A. Scolyer
Employment - Royal Prince Alfred Hospital
Honoraria - GlaxoSmithKline; Harvard Medical School; Wake Forest School of Medicine
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); Evaxion Biotech; GlaxoSmithKline; Merck Sharp & Dohme; metaoptima; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; Novartis; Novartis; Provectus Biopharmaceuticals; QBiotics; Roche
Research Funding - Melanoma Research Alliance (MRA); National Health and Medical Research Council; National Health and Medical Research Council; National Health and Medical Research Council; The Ainsworth Foundation (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
(OPTIONAL) Uncompensated Relationships - Melanoma Institute Australia
 
Michael A. Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; NanoString Technologies; Novartis; Pfizer
Research Funding - ABM (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lead Pharma (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)